About takeda pharmaceutical co. ltd. - TAK
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following business divisions: Gastrointestinal Diseases, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
TAK At a Glance
Takeda Pharmaceutical Co., Ltd.
2-1-1 Nihonbashi-Honcho
Osaka, Osaka 103-8668
| Phone | 81-3-3278-2111 | Revenue | 30.05B | |
| Industry | Pharmaceuticals: Major | Net Income | 707.96M | |
| Sector | Health Technology | 2025 Sales Growth | 1.788% | |
| Fiscal Year-end | 03 / 2026 | Employees | 47,455 | |
| View SEC Filings |
TAK Valuation
| P/E Current | 67.151 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 66.325 |
| Price to Sales Ratio | 1.589 |
| Price to Book Ratio | 1.009 |
| Price to Cash Flow Ratio | 7.56 |
| Enterprise Value to EBITDA | 8.693 |
| Enterprise Value to Sales | 2.635 |
| Total Debt to Enterprise Value | 0.43 |
TAK Efficiency
| Revenue/Employee | 633,289.189 |
| Income Per Employee | 14,918.449 |
| Receivables Turnover | 6.197 |
| Total Asset Turnover | 0.308 |
TAK Liquidity
| Current Ratio | 1.006 |
| Quick Ratio | 0.52 |
| Cash Ratio | 0.154 |
TAK Profitability
| Gross Margin | 53.589 |
| Operating Margin | 13.697 |
| Pretax Margin | 3.909 |
| Net Margin | 2.356 |
| Return on Assets | 0.726 |
| Return on Equity | 1.499 |
| Return on Total Capital | 0.88 |
| Return on Invested Capital | 0.898 |
TAK Capital Structure
| Total Debt to Total Equity | 73.375 |
| Total Debt to Total Capital | 42.321 |
| Total Debt to Total Assets | 35.714 |
| Long-Term Debt to Equity | 64.53 |
| Long-Term Debt to Total Capital | 37.22 |